Abivax S.A. (ABVX) shareholders

ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 1/30

$90.20−1.24 (-1.36%)

Close on Nov 12, 2026Market cap $7.08BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions

55M

Shares held, 13F filers

Institutional holders

302

91 new, 40 sold out

Net institutional buying

In Q2 2026

Insider trades, 12 months

0 buys · 0 sales

Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

Holder	Shares	% of class	Filing	As of
Sofinnova Crossover I SLP Joint filing with Sofinnova Partners SAS (11.40%), Antoine Papiernik (11.40%) and 4 more	9,599,478	11.40%	13D (active) amendment	Jul 23, 2025
Cedric Moreau Joint filing with Sofinnova Crossover I SLP (9.40%), Sofinnova Partners SAS (9.40%) and 4 more	8,399,478	9.40%	13D (active) amendment	Oct 28, 2025
Joseph Anderson Joint filing with Sofinnova Crossover I SLP (11.00%), Sofinnova Partners SAS (11.00%) and 4 more	7,794,478	11.00%	13D (active) amendment	Feb 14, 2025
Chen Yu Joint filing with TCG Crossover GP I, LLC (5.70%), TCG Crossover Fund I, L.P. (5.70%)	6,007,834	7.00%	13G (passive) amendment	Jun 30, 2026
Invus Public Equities, L.P. Joint filing with Invus Public Equities Advisors, LLC (8.50%), Invus Global Management, LLC (8.50%) and 2 more	5,403,985	8.50%	13G (passive)	Sep 2, 2022
Raymond Debbane Joint filing with Invus Public Equities, L.P. (6.00%), Invus Public Equities Advisors, LLC (6.00%) and 2 more	4,825,759	6.00%	13G (passive) amendment	Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

Holder	Shares	% of ABVX	Value	Change	% of portfolio
TCG Crossover Management, LLC	6,007,834	–	$800.60M	−473,251	19.24%
Darwin Global Management, Ltd.	3,621,583	–	$348.22M	+152,926	9.26%
Helikon Investments Ltd	2,787,131	–	$371.41M	+1,773,807	11.10%
Vestal Point Capital, LP	2,349,443	–	$313.09M	+849,443	7.32%
Jupiter Topco LLC	1,913,933	–	$255.13M	New	0.10%
UBS Group AG	1,844,918	–	$245.85M	−2,702,488	0.03%
ADAR1 Capital Management, LLC	1,804,703	–	$240.49M	+410,684	11.01%
Caligan Partners LP	1,557,924	–	$207.61M	+96,000	9.77%
Citadel Advisors LLC	1,438,352	–	$191.67M	+894,014	0.02%
Morgan Stanley	1,432,185	–	$190.85M	−272,773	0.01%
Westfield Capital Management Co LP	1,309,825	–	$174.55M	−13,113	0.57%
Ra Capital Management, L.P.	1,132,557	–	$150.92M	New	1.31%
Norges Bank	1,100,000	–	$146.59M	New	0.01%
Susquehanna International Group, Llp	1,053,896	–	$140.44M	+672,614	0.01%
Logos Global Management LP	1,024,000	–	$136.46M	+349,000	5.87%
Octagon Capital Advisors LP	993,000	–	$132.33M	+316,000	11.89%
Bank Of America Corp /De/	971,439	–	$129.45M	+235,710	0.01%
Eversept Partners, LP	913,880	–	$121.78M	−20,543	6.32%
Goldman Sachs Group Inc	792,712	–	$105.64M	+443,915	0.01%
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	765,332	–	$101.99M	−583	5.59%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

Quarter	Holders	Shares held	New / added	Reduced / closed	Shares bought	Shares sold
Q2 2026	302	55M	91 / 98	100 / 40	18M	13M
Q1 2026	254	50M	53 / 112	74 / 44	6M	12M
Q4 2025	247	56M	107 / 76	50 / 24	12M	8M
Q3 2025	165	52M	130 / 16	17 / 8	33M	11M
Q2 2025	43	31M	6 / 16	11 / 9	2M	4M
Q1 2025	46	32M	8 / 18	11 / 10	5M	3M
Q4 2024	48	30M	14 / 14	9 / 6	5M	3M
Q3 2024	40	27M	4 / 17	12 / 2	2M	4M
Q2 2024	38	29M	4 / 13	13 / 2	7M	3M
Q1 2024	36	25M	12 / 9	7 / 6	4M	2M
Q4 2023	30	23M	30 / 0	0 / 0	23M	0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

85 funds held ABVX in Q2 2026, 12% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

Fund	Shares	% of ABVX	Value	% of fund	As of
Alger Focus Equity Fund	607,577	–	$75.90M	1.07%	Jul 31, 2026
iShares Biotechnology ETF	458,824	–	$61.14M	0.67%	Jun 30, 2026
Eventide Healthcare & Life Sciences Fund	394,782	–	$52.61M	2.94%	Jun 30, 2026
Alger Spectra Fund	334,177	–	$41.75M	0.97%	Jul 31, 2026
Harbor Small Cap Growth Fund	296,560	–	$37.05M	1.39%	Jul 31, 2026
Alger Capital Appreciation Institutional Fund	259,984	–	$32.48M	0.94%	Jul 31, 2026
Select Biotechnology Portfolio	255,300	–	$33.86M	0.64%	May 31, 2026
Alger Capital Appreciation Fund	208,404	–	$26.03M	0.95%	Jul 31, 2026
Janus Henderson Global Life Sciences Fund	179,100	–	$23.87M	0.41%	Jun 30, 2026
Fidelity Growth Company Fund	139,580	–	$18.51M	0.02%	May 31, 2026
Alger Small Cap Focus Fund	116,210	–	$14.52M	1.70%	Jul 31, 2026
SmallCap Fund	111,567	–	$13.94M	0.67%	Jul 31, 2026
T. Rowe Price New Horizons Fund, Inc.	109,661	–	$14.61M	0.10%	Jun 30, 2026
Franklin Biotechnology Discovery Fund	109,022	–	$13.62M	1.18%	Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.	104,054	–	$13.87M	0.12%	Jun 30, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding

–

4M shares short

Days to cover

4.6

At 1M shares a day

Change since last report

-43.3%

From 7M shares

Short volume, 20 days

33.8%

Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Abivax's stock actually held short. Settlement fails (shares not delivered on time) peaked at 18,127 shares on Sep 25, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

Seller	Filed	Shares	Market value	Planned sale	Acquired through
Sofinnova Crossover I SLP Affiliate	Jan 8, 2026	1,000,000	$133.70M	Jan 8, 2026	Private Placement
Sofinnova Crossover I SLP Affiliate	Oct 28, 2025	1,200,000	$111.30M	Oct 28, 2025	Purchased in IPO

See a number that looks wrong?